[Hyperthermic intrathoracic chemotherapy in thoracic surgery].

[Hyperthermic intrathoracic chemotherapy in thoracic surgery].
Chirurg. 2019 Jun 19;:
Authors: Hofmann HS, Ried M
Abstract
In regional chemotherapy of the pleural space a differentiation is made between intrapleural hyperthermic perfusion (IHP) and hyperthermic intrathoracic chemotherapy (HITOC). The HITOC in particular is carried out as an additive procedure after surgical cytoreduction of the pleural tumor manifestation. The main indications are for malignant pleural mesothelioma and thymoma with pleural spread (stage IVa), whereas treatment of secondary pleural carcinomatosis is indicated only in selected patients suitable for resection followed by HITOC. Cisplatin is the standard chemotherapeutic agent and a concentration of 150-175 mg/m2 body surface area is recommended. Postoperative, HITOC-related complications (e.g. renal insufficiency) can be minimized by an adapted perioperative management. Safety measures should be accomplished adhered to for the protection of personnel. The aim of HITOC is to achieve a better local tumor control with a corresponding longer recurrence-free and overall survival.
PMID: 31218434 [PubMed - as supplied by publisher]

Source: Der Chirurg - June 18, 2019 Category: Surgery Authors: Hofmann HS, Ried M Tags: Chirurg Source Type: research